Literature DB >> 20557278

Liquid chromatography-tandem mass spectrometry method for simultaneous quantification of four triazole antifungal agents in human plasma.

Marie-Clémence Verdier1, Danièle Bentué-Ferrer, Olivier Tribut, Eric Bellissant.   

Abstract

BACKGROUND: Invasive fungal infections are an increasing cause of morbidity and mortality. Triazole antifungal agents are recommended for the prevention and treatment of such infections. Their broad inter- and intra-individual pharmacokinetic variability and the high probability of drug-drug interactions justify therapeutic drug monitoring (TDM). We developed a liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of four triazole antifungal agents (fluconazole, itraconazole, posaconazole, voriconazole) and one of their metabolites (hydroxy-itraconazole) in human plasma.
METHODS: After protein precipitation with acetonitrile (ACN), a C18 column was used for separation with a mobile phase consisting of 0.1% formic acid, water and ACN in a linear gradient from 20% to 70%, over 10 min. Detection was performed by electrospray ionization and quantification was performed using selected reaction monitoring transitions.
RESULTS: Total run time was 15 min. The method was validated for a range of 0.1-12 μg/mL. Coefficients of variation were <9.5% and <13.8%, and accuracies were between -5.4% and +7.7% and between -10.8% and +10.4%, for intra- and inter-day validations, respectively.
CONCLUSIONS: This method appears to be well suited to routine hospital practice for the TDM of triazole antifungal agents considering its time of analysis, range of concentrations measured, precision and accuracy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20557278     DOI: 10.1515/CCLM.2010.252

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  6 in total

1.  Population Pharmacokinetics of Posaconazole Tablets and Monte Carlo Simulations To Determine whether All Patients Should Receive the Same Dose.

Authors:  A Petitcollin; C Boglione-Kerrien; C Tron; S Nimubona; S Lalanne; F Lemaitre; E Bellissant; M-C Verdier
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

2.  Safety study and therapeutic drug monitoring of the oral tablet formulation of posaconazole in patients with haematological malignancies.

Authors:  C Boglione-Kerrien; S Picard; C Tron; S Nimubona; J-P Gangneux; S Lalanne; F Lemaitre; E Bellissant; M-C Verdier; A Petitcollin
Journal:  J Cancer Res Clin Oncol       Date:  2017-09-20       Impact factor: 4.553

3.  A Comparative Study of Newly Developed HPLC-DAD and UHPLC-UV Assays for the Determination of Posaconazole in Bulk Powder and Suspension Dosage Form.

Authors:  Dalia A Hamdy; Tarek S Belal
Journal:  J Anal Methods Chem       Date:  2014-09-03       Impact factor: 2.193

4.  A sensitive method for analyzing fluconazole in extremely small volumes of neonatal serum.

Authors:  Jumpei Saito; Ayano Tanzawa; Yuka Kojo; Hidehiko Maruyama; Tetsuya Isayama; Kensuke Shoji; Yushi Ito; Akimasa Yamatani
Journal:  J Pharm Health Care Sci       Date:  2020-07-01

Review 5.  Interpersonal Factors in the Pharmacokinetics and Pharmacodynamics of Voriconazole: Are CYP2C19 Genotypes Enough for Us to Make a Clinical Decision?

Authors:  Xuefeng Zhong; Xunliang Tong; Yang Ju; Xiaoman Du; Yanming Li
Journal:  Curr Drug Metab       Date:  2018       Impact factor: 3.731

6.  Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.

Authors:  Yukihiro Hamada; Issei Tokimatsu; Hiroshige Mikamo; Masao Kimura; Masafumi Seki; Shunji Takakura; Norio Ohmagari; Yoshiko Takahashi; Kei Kasahara; Kazuaki Matsumoto; Kenji Okada; Masahiro Igarashi; Masahiro Kobayashi; Takahiro Mochizuki; Yoshifumi Nishi; Yusuke Tanigawara; Toshimi Kimura; Yoshio Takesue
Journal:  J Infect Chemother       Date:  2013-05-15       Impact factor: 2.211

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.